Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Cancer Cell2021Vol. 39(3), pp. 346–360.e7
Citations Over TimeTop 1% of 2021 papers
Carl M. Gay, C. Allison Stewart, Elizabeth M. Park, Lixia Diao, Sarah M. Groves, Simon Heeke, Barzin Y. Nabet, Junya Fujimoto, Luisa M. Solis, Wei Lü, Yuanxin Xi, Robert J. Cardnell, Qi Wang, Giulia Fabbri, Kasey R. Cargill, Natalie I. Vokes, Kavya Ramkumar, Bingnan Zhang, Carminia Maria Della Corte, Paul Robson, Stephen G. Swisher, Jack A. Roth, Bonnie S. Glisson, David S. Shames, Ignacio I. Wistuba, Jing Wang, Vito Quaranta, John D. Minna, John V. Heymach, Lauren A. Byers
Related Papers
- → The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin(2001)86 cited
- → Antitumor effect of radioactive cisplatin (191Pt) on nude mice(2001)37 cited
- Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines.(1994)
- → Comparative antitumour activity of cisplatin and two new cisplatin‐analogues JM8 and JM9 in human testicular carcinoma xenografts(1987)3 cited
- The Relationship between Expression of 1-Cys Peroxiredoxin and Resistance to Cisplatin in Epithelial Ovarian Cancer Cell Lines.(2006)